Want to join the conversation?
$VRX said it is pleased with the successful outcome of the Brodalumab FDA panel on July 19, 2016 and looks forward to progressing with this important drug through the approval process. The company continues to improve its managed care position, and maintained key product access on the ESI and Caremark exclusion list.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.